Skip to content

    Heart Failure Health Center

    Font Size
    A
    A
    A

    Drug 'New Hope' Against Heart Failure: Expert

    Experimental medication beat standard treatment at reducing hospitalizations, cardiovascular deaths

    WebMD News from HealthDay

    By Steven Reinberg

    HealthDay Reporter

    SATURDAY, Aug. 30, 2014 (HealthDay News) -- In a head-to-head comparison, an experimental drug was more effective than standard treatment at preventing deaths and hospitalizations in heart failure patients.

    According to the study authors, the trial was stopped early because of the marked benefit of the new drug, dubbed LCZ696.

    In the trial, 26.5 percent of those getting the standard medication, enalapril (Vasotec), either died or were hospitalized due to heart failure, compared with 21.8 percent of those on the new drug. Enalapril belongs to a class of blood pressure-lowering medications known as ACE inhibitors.

    "LCZ696 could become the new gold standard, replacing ACE inhibitors," said lead researcher Dr. John McMurray, a professor of cardiology at the British Heart Foundation Cardiovascular Research Center at the University of Glasgow, in Scotland.

    LCZ696 combines two blood pressure drugs -- an angiotensin II receptor blocker (ARB) and the neprilysin inhibitor known as sacubitril.

    "We found that LCZ696 was superior to the gold-standard ACE inhibitor for heart failure -- an ACE inhibitor being the absolute cornerstone of treatment for this problem," he said.

    Not only did LCZ696 beat enalapril, but it did that even when added to other treatments, McMurray noted.

    "The new treatment was very well tolerated, with no significant safety concerns," he added.

    The report was published online Aug. 30 in the New England Journal of Medicine, to coincide with a presentation at the European Society of Cardiology annual meeting in Barcelona. The trial was funded by Novartis, the maker of LCZ696.

    Dr. Mariell Jessup, a professor of medicine at the University of Pennsylvania's Perelman School of Medicine, said, "There is new hope for heart failure."

    She added, "We have not had a new drug for heart failure for many years. LCZ696 is a unique compound that may represent a new approach."

    Doctors have relied on ACE inhibitors for over two decades, she said. According to Jessup, who wrote an accompanying editorial, "Newer drugs that work via alternate pathways may [show] benefit beyond the medical therapy that is used today."

    Today on WebMD

    Compressed heart
    Article
    Salt Shockers
    Slideshow
     
    Inside A Heart Attack
    Slideshow
    lowering blood pressure
    SLIDESHOW
     

    Mechanical Heart
    Article
    Omega 3 Overview Slideshow
    Slideshow
     
    Atrial Fibrillation Guide
    Slideshow
    Simple Steps to Lower Cholesterol
    Slideshow
     

    Compressed heart
    Article
    FAQ Heart Failure
    Article
     
    Cholesterol Confusion
    Health Check
    Resolved To Quit Smoking
    Slideshow
     

    WebMD Special Sections